Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 From record-breaking litigation wins to billion-dollar deals and global policy leadership, this year’s cohort features the women shaping the future of intellectual property law.

Careers

WilmerHale trade secrets expert moves to new firm

7 July 2026 Focusing on technology and life sciences clients, the new San Fran-based Debevoise & Plimpton hire brings both in-house and private practice litigation experience across trade secrets and commercial disputes.

Europe

UPC revives patent, but timing sinks Guardant’s appeal

6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.

More features

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

UPC revives patent, but timing sinks Guardant’s appeal

China’s medtech shake-up forces rethink on pricing, IP and innovation

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Vinson & Elkins grows West Coast patent and trade secrets bench

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features